Claims for Patent: 7,521,041

Summary for Patent: 7,521,041

Title:	Biphenyl compounds useful as muscarinic receptor antagonists
Abstract:	This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Inventor(s):	Mammen; Mathai (Redwood Shores, CA), Ji; Yu-Hua (Redwood City, CA), Mu; YongQi (Los Altos, CA), Husfeld; Craig (Redwood City, CA), Li; Li (Sunnyvale, CA)
Assignee:	Theravance, Inc. (South San Francisco, CA)
Application Number:	11/974,318
Patent Claims:	1. A method of determining the effect of antagonizing a muscarinic receptor on a biological system or sample comprising a muscarinic receptor, the method comprising: (a) contacting a first sample of the biological system or sample with a muscarinic agonist; (b) measuring the amount of cyclic adenosine monophosphate (cAMP) produced in the first sample; (c) contacting a second sample of the biological system or sample with the muscarinic agonist and a muscarinic receptor-antagonizing amount of a compound; (d) measuring the amount of cAMP produced in the second sample; and (e) comparing the amount of cAMP in step (b) with the amount in step (d); wherein the compound in step (c) has the formula: ##STR00037## wherein: a is 0 or 1; R.sup.1 is halo; b is 0 or 1; R.sup.2 is halo; m is 0 or 1; R.sup.4 is selected from hydrogen and (1-4C)alkyl; s is 0, 1 or 2; Ar.sup.1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur; wherein the phenylene or heteroarylene group is substituted with (R.sup.5).sub.q where q is 0 or an integer from 1 to 4 and each R.sup.5 is independently selected from halo, hydroxy, (1-4C)alkyl and (1-4C)alkoxy; t is 0, 1 or 2; n is 0 or an integer from 1 to 3; p is 0 or 1; and R.sup.7 and R.sup.8 are independently hydrogen or (1-4C)alkyl; wherein each alkyl group in R.sup.7 and R.sup.8 is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or stereoisomer thereof. 2. A method for antagonizing a muscarinic receptor in a mammal which comprises administering to the mammal, a therapeutically effective amount of the compound having the formula: ##STR00038## wherein: a is 0 or 1; R.sup.1 is halo; b is 0 or 1; R.sup.2 is halo; m is 0 or 1; R.sup.4 is selected from hydrogen and (1-4C)alkyl; s is 0, 1 or 2; Ar.sup.1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur; wherein the phenylene or heteroarylene group is substituted with (R.sup.5).sub.q where q is 0 or an integer from 1 to 4 and each R.sup.5 is independently selected from halo, hydroxy, (1-4C)alkyl and (1-4C)alkoxy; t is 0, 1 or 2; n is 0 or an integer from 1 to 3; p is 0 or 1; and R.sup.7 and R.sup.8 are independently hydrogen or (1-4C)alkyl; wherein each alkyl group in and R.sup.8 is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or stereoisomer thereof. 3. A method of determining the effect of antagonizing a muscarinic receptor on a biological system or sample comprising a muscarinic receptor, the method comprising: (a) contacting a first sample of the biological system or sample with a muscarinic agonist and guanosine 5'-O-(.gamma.-thio)triphosphate (GTP.gamma.S); (b) measuring the amount of GTP.gamma.S binding in the first sample; (c) contacting a second sample of the biological system or sample with the muscarinic agonist, GTP.gamma.S, and a muscarinic receptor-antagonizing amount of a compound; (d) measuring the amount of GTP.gamma.S binding in the second sample; and (e) comparing the amount of GTP.gamma.S binding in step (b) with the amount in step (d); wherein the compound in step (c) has the formula: ##STR00039## wherein: a is 0 or 1; R.sup.1 is halo; b is 0 or 1; R.sup.2 is halo; m is 0 or 1; R.sup.4 is selected from hydrogen and (1-4C)alkyl; s is 0, 1 or 2; Ar.sup.1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur; wherein the phenylene or heteroarylene group is substituted with (R.sup.5).sub.q where q is 0 or an integer from 1 to 4 and each R.sup.5 is independently selected from halo, hydroxy, (1-4C)alkyl and (1-4C)alkoxy; t is 0, 1 or 2; n is 0 or an integer from 1 to 3; p is 0 or 1; and R.sup.7 and R.sup.8 are independently hydrogen or (1-4C)alkyl; wherein each alkyl group in R.sup.7 and R.sup.8 is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or stereoisomer thereof. 4. A method of determining the effect of antagonizing a muscarinic receptor on a biological system or sample comprising a muscarinic receptor, the method comprising: (a) contacting a first sample of the biological system or sample with a muscarinic agonist; (b) measuring the amount of calcium released in the first sample; (c) contacting a second sample of the biological system or sample with the muscarinic agonist and a muscarinic receptor-antagonizing amount of a compound; (d) measuring the amount of calcium released in the second sample; and (e) comparing the amount of calcium released in step (b) with the amount in step (d); wherein the compound in step (c) has the formula: ##STR00040## wherein: a is 0 or 1; R.sup.1 is halo; b is 0 or 1; R.sup.2 is halo; m is 0 or 1; R.sup.4 is selected from hydrogen and (1-4C)alkyl; s is 0, 1 or 2; Ar.sup.1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur; wherein the phenylene or heteroarylene group is substituted with (R.sup.5).sub.q where q is 0 or an integer from 1 to 4 and each R.sup.5 is independently selected from halo, hydroxy, (1-4C)alkyl and (1-4C)alkoxy; t is 0, 1 or 2; n is 0 or an integer from 1 to 3; p is 0 or 1; and R.sup.7 and R.sup.8 are independently hydrogen or (1-4C)alkyl; wherein each alkyl group in R.sup.7 and R.sup.8 is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or stereoisomer thereof. 5. A method of determining the effect of antagonizing a muscarinic receptor on a mammal, the method comprising: (a) administering a muscarinic receptor-antagonizing amount of a compound to the mammal; (b) inducing bronchoconstriction in the mammal; (c) measuring pulmonary resistance; wherein the compound in step (b) has the formula: ##STR00041## wherein: a is 0 or 1; R.sup.1 is halo; b is 0 or 1; R.sup.2 is halo; m is 0 or 1; R.sup.4 is selected from hydrogen and (1-4C)alkyl; s is 0, 1 or 2; Ar.sup.1 represents a phenylene group or a (3-5C)heteroarylene group containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur; wherein the phenylene or heteroarylene group is substituted with (R.sup.5).sub.q where q is 0 or an integer from 1 to 4 and each R.sup.5 is independently selected from halo, hydroxy, (1-4C)alkyl and (1-4C)alkoxy; t is 0, 1 or 2; n is 0 or an integer from 1 to 3; p is 0 or 1; and R.sup.7 and R.sup.8 are independently hydrogen or (1-4C)alkyl; wherein each alkyl group in R.sup.7 and R.sup.8 is optionally substituted with 1 to 5 fluoro substituents; or a pharmaceutically acceptable salt or stereoisomer thereof. 6. The method of claim 1, 3, or 4, wherein the biological system or sample is selected from cells, cellular extracts, plasma membranes, tissue samples, and mammals. 7. The method of claim 1, which further comprises contacting a third sample of the biological system or sample with a test compound; measuring the amount of cAMP produced in the third sample; and comparing the amount of cAMP produced in the third sample with the amount of cAMP in step (b) and step (d). 8. The method of claim 7, wherein the comparison is used to identify test compounds having about equal or superior blockade of agonist-mediated inhibition of cAMP accumulation than the compound of step (c). 9. The method of claim 1, wherein the muscarinic agonist is selected from oxotremorine, acetylcholine, pilocarpine, and methacholine. 10. The method of claim 3, wherein the muscarinic agonist is selected from oxotremorine, acetylcholine, pilocarpine, and methacholine. 11. The method of claim 3, which further comprises contacting a third sample of the biological system or sample with a test compound; measuring the amount of GTP.gamma.S binding in the third sample; and comparing the amount of GTP.gamma.S binding in the third sample with the amount of GTP.gamma.S binding in step (b) and step (d). 12. The method of claim 11, wherein the comparison is used to identify test compounds having about equal or superior blockade of agonist-mediated GTP.gamma.S binding than the compound of step (c). 13. The method of claim 4, wherein the muscarinic agonist is selected from oxotremorine, acetylcholine, pilocarpine, and methacholine. 14. The method of claim 4, which further comprises contacting a third sample of the biological system or sample with a test compound; measuring the amount of calcium released in the third sample; and comparing the amount of calcium released in the third sample with the amount of calcium released in step (b) and step (d). 15. The method of claim 14, wherein the comparison is used to identify test compounds having about equal or superior blockade of agonist-mediated calcium release than the compound of step (c). 16. The method of claim 5, wherein bronchoconstriction is induced by administering acetylcholine to the mammal. 17. The method of claim 1, 2, 3, 4, or 5, wherein a and b each represent 0. 18. The method of claim 1, 2, 3, 4, or 5, wherein m is 0, is 0 and t is 1. 19. The method of claim 1, 2, 3, 4, or 5, wherein the --CONR.sup.7R.sup.8 group is in the para position, and n is 2. 20. The method of claim 1, 2, 3, 4, or 5, wherein Ar.sup.1 represents phen-1,3-ylene, phen-1,4-ylene, 2,4-thienylene or 2,5-thienylene; wherein the phenylene or thienylene group is optionally substituted with one or two R.sup.5 substituents. 21. The method of claim 1, 2, 3, 4, or 5, wherein a and b each represent 0; m is 0; s is 0; t is 1; Ar.sup.1 represents phen-1,4-ylene optionally substituted with one or two R.sup.5 substituents; n is 2 and the --CONR.sup.7R.sup.8 group is in the para position; and R.sup.8 is hydrogen. 22. The method of claim 1, 2, 3, 4, or 5, wherein the compound is biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester or a pharmaceutically acceptable salt thereof.